VRTX Financial Facts

Total revenues: 328.37M
Total costs and expenses: 766.66M
See Full Income Statement

Accrued restructuring expense, current portion: 4.91M
Accumulated deficit: -3.83B
See Full Balance Sheet

Earnings History for Vertex Pharmaceuticals Incorporated (VRTX)

  |   Expand Research on VRTX
Next EPS Date 7/29/13 *Est. EPS Growth Rate -94.5% *Last Qtr.
Average EPS % Beat Rate +55.0% Revenue Growth Rate -25.1% *Last Qtr.
Average % Move 1-Wk after EPS -2.5%    
Date  Qtr EPS Cons. Surprise Revs Cons. Estimize EPS/Revs Gd. % Since Details
4/30/13 Q113 $0.03-$0.18 +$0.21$328.4M$308.6M N/A / N/A = +2.2% Details
1/29/13 Q412 $0.04-$0.07 +$0.11$334M$318.53M N/A / N/A = +69.1% Details
11/1/12 Q312 $0.13$0.19 -$0.06$336M$377.14M $0.20 / $379.16M N/A +55.1% Details
7/30/12 Q212 $0.46$0.59 -$0.13$418.3M$472.16M $0.68 / $511.91M N/A +57.1% Details
4/26/12 Q112 $0.55$0.66 -$0.11$438.7M$473.37M $0.61 / $486.45M N/A +109.2% Details
2/2/12 Q411 $0.86$0.70 +$0.16$563.3M$518.36M $0.77 / $535.18M N/A +104.6% Details
10/27/11 Q311 $0.70$0.17 +$0.53$659.2M$343.42M N/A / N/A N/A +84.7% Details
7/28/11 Q211 -$0.85-$0.95 +$0.10$114.42M$31.62M N/A / N/A N/A +63.6% Details
Like VRTX Earnings? Also take a look at GILD, BMY, IDIX, MRK

VRTX Earnings News